Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
AstraZeneca Expands U.S. Investment Plan
Healthy Returns: AstraZeneca expands U.S. investment plan on confidence in economy
A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions.AstraZeneca said it is doubling down on its investment in its U.
AstraZeneca Expands U.S. Investment Plan
AstraZeneca
said it plans to pump $2 billion in new investment into the U.S., one of the first major foreign companies to commit significant new spending to the country after Donald Trump’s election win. The decision to go ahead with the spending ...
AstraZeneca Raises Outlook, Plans U.S. Investment
AstraZeneca raised its full-year guidance after third-quarter results topped analysts’ expectations, boosted by its cancer and diabetes medicines, and laid out plans for a multibillion-dollar investment in the U.
Astra Invests $3.5 Billion in US as Cancer Sales Rise
AstraZeneca Plc raised its annual forecast, driven by strong demand for its blockbuster cancer drugs, and revealed a plan to invest $3.5 billion in the US business by the end of 2026.
2d
AstraZeneca talks up US growth as China problems fester
AstraZeneca Plc is increasingly looking to the US for growth as its once fast-expanding China business faces challenges amid ...
Outsourcing-pharma
1d
AstraZeneca doubles down on US manufacturing with $3.5 billion investment
AstraZeneca has become the latest big pharma company to devote new cash to its US manufacturing muscle this year as it ...
3d
on MSN
AstraZeneca lifts 2024 outlook after Q3 beat, doubles down on US investments
Drugmaker AstraZeneca lifted its annual sales and profit forecast for the second time this year on Tuesday, helped by strong ...
STAT
3d
Pharmalittle: We’re reading about 23andMe retrenching, AstraZeneca reworking cancer drug plans, and more
In closing its therapeutics division and laying off 200 people, 23andMe ended an audacious bet it made nearly a decade ago — ...
Bisnow
2d
AstraZeneca To Invest $3.5B To Grow U.S. Footprint
Cambridge, England-based biopharmaceutical giant
AstraZeneca
is pouring billions of dollars into properties in the United ...
Reuters
3d
AstraZeneca: 450 million pound investment in UK under review amid talks with govt
LONDON, Nov 12 (Reuters) - London-listed drugmaker
AstraZeneca
(AZN.L), opens new tab said its plan to invest 450 million ...
STAT
3d
AstraZeneca, Daiichi Sankyo change strategy on closely watched cancer drug
LONDON — AstraZeneca said Tuesday it has had to resubmit a closely watched medicine for U.S. approval in a different form of ...
1d
AstraZeneca: Strong Growth Potential And Market Volatility Offer Opportunity
AstraZeneca PLC aims for $80 billion revenue by 2030 through strong growth in oncology, biopharmaceuticals, and rare diseases ...
3d
AstraZeneca Raises Outlook on Earnings, Sales Beat
The pharmaceutical giant raised its full-year guidance after third-quarter revenue and core earnings per share topped ...
Business Insider
1d
AstraZeneca: Overcoming Short-term Challenges with Robust Long-term Potential
Bernstein analyst Justin Smith maintained a Buy rating on
AstraZeneca
(AZN – Research Report) today and set a price target of p18,000.00. Justin Smith has given his Buy rating due to a combination ...
3d
AstraZeneca says detained China head has lawyer, but company still in dark
AstraZeneca's China president Leon Wang, who was detained last month by Chinese authorities, is in touch with a lawyer but ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Related topics
China
United States
Research and development
Feedback